I am a board certified urologist who completed a fellowship in urologic oncology at the University of California, San Francisco in 1998. I remained on faculty in the Department of Urology at UCSF from 1998-2003, during which time I cared for patients with prostate, bladder, kidney and testis cancer. I also participated in basic science, translational and clinical research, authoring or co-authoring nearly 90 research articles and 20 book chapters. I transitioned to private practice in 2003 and continued to focus on the care of patients with urologic cancer. I was director of the prostate cancer program at Marin General Hospital and served as chair of the Division of Urology and Chief of the Department of Surgery. In June 2014, I began the Master of Public Health program at the Johns Hopkins Bloomberg School of Public Health and received my MPH degree December 2016. I served as Vice President and Surgical Director at Patient Doctor Technologies, Inc (dba Doctella.com) from June 2015 through June 2017. Doctella created a cloud-based platform enabling patients and their families to become effective partners in their own healthcare. I joined Bristol-Myers Squibb in July 2017 as a Clinical Trial Lead for the Bladder Cancer program. As a Clinical Trial Lead, I translated strategy into protocols and action plans with a focus on early stage bladder cancer. In March 2019, I began a new role as Program Lead, External Opportunity Assessments and Evaluations and worked with Business Development, Commercial and the broader Research and Development organization at BMS to support clinical assessments of external oncology opportunities. I moved into the role of Clinical Development Lead for the bempegaldesleukin program at BMS in March 2020. In this role I was accountable for the clinical contribution to the development of bempegaldesleukin in multiple tumor indications. I was subsequently appointed Global Development Program Lead for the bempegaldesleukin program at BMS and was accountable for the establishment and execution of the global integrated development strategy for bempegaldesleukin. Most recently, I was appointed Global Development Program lead for the alnuctmab program at BMS. Alnuctamab is a potential best-in-class BCMA targeting T-cell engaging bispecific antibody that is being developed in multiple myeloma. In my current role I lead the cross-functional global project team with accountability for alnuctamab strategy and leadership throughout the alnuctamab lifecycle.

• 

  Advisor in CareTech Human

  Join the Smart Toilet Revolution